Thus, our in-silico findings not only suggest a link between the disrupted standard and wild ADGRL3 structure and its metabolic regulation consequences but grant a further exploration of in vitro experiments to define and evaluate the possible therapeutic possibility for both children and adults with ADHD. This evidence concerns the gene ADGRL3 and attention deficit-hyperactivity disorder.